{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:04:34Z","timestamp":1792807474340,"version":"4.5.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T00:00:00Z","timestamp":1621555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Clin Microbiol Antimicrob"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Drug repurposing otherwise known as drug repositioning or drug re-profiling is a time-tested approach in drug discovery through which new medical uses are being established for already known drugs. Antibiotics are among the pharmacological agents being investigated for potential anti-SARS-COV-2 activities. The antibiotics are used either to resolve bacterial infections co-existing with COVID-19 infections or exploitation of their potential antiviral activities. Herein, we aimed to review the various antibiotics that have been repositioned for the management of COVID-19.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This literature review was conducted from a methodical search on PubMed and Web of Science regarding antibiotics used in patients with COVID-19 up to July 5, 2020.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Macrolide and specifically azithromycin is the most common antibiotic used in the clinical management of COVID-19. The other antibiotics used in COVID-19 includes teicoplanin, clarithromycin, doxycycline, tetracyclines, levofloxacin, moxifloxacin, ciprofloxacin, and cefuroxime. In patients with COVID-19, antibiotics are used for their immune-modulating, anti-inflammatory, and antiviral properties. The precise antiviral mechanism of most of these antibiotics has not been determined. Moreover, the use of some of these antibiotics against SARS-CoV-2 infection remains highly controversial and not widely accepted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The heavy use of antibiotics during the COVID-19 pandemic would likely worsen antibiotic resistance crisis. Consequently, antibiotic stewardship should be strengthened in order to prevent the impacts of COVID-19 on the antibiotic resistance crisis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12941-021-00444-9","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T12:02:47Z","timestamp":1621598567000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Repurposing of antibiotics for clinical management of COVID-19: a narrative review"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0950-2205","authenticated-orcid":false,"given":"Abdourahamane","family":"Yacouba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Olowo-okere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismaeel","family":"Yunusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,21]]},"reference":[{"key":"444_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Bo Yang JS, Ma X, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727\u201333.","journal-title":"N Engl J Med"},{"key":"444_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s15010-020-01401-y","volume":"48","author":"ZJ Cheng","year":"2020","unstructured":"Cheng ZJ, Shan J. 2019 Novel coronavirus: where we are and what we know. Infection. 2020;48:155\u201363.","journal-title":"Infection"},{"key":"444_CR3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s12098-020-03263-6","volume":"87","author":"T Singhal","year":"2020","unstructured":"Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020;87:281\u20136.","journal-title":"Indian J Pediatr"},{"key":"444_CR4","unstructured":"World Health Organization (WHO). WHO Director-General\u2019s opening remarks at the media briefing on COVID-19\u201311 March 2020. WHO. 2020. https:\/\/www.who.int\/director-general\/speeches\/detail\/. Accessed 9 Sept 2020."},{"key":"444_CR5","unstructured":"University JH. COVID-19 Map. Johns Hopkins Coronavirus Resource Center. 2020. https:\/\/coronavirus.jhu.edu\/map.html. Accessed 9 Sept 2020."},{"key":"444_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ijsu.2020.04.018","volume":"78","author":"M Nicola","year":"2020","unstructured":"Nicola M, Alsafi Z, Sohrabi C, Kerwan A, Al-jabir A. The socio-economic implications of the coronavirus pandemic (COVID-19): a review. Int J Surg. 2020;78:185\u201393.","journal-title":"Int J Surg"},{"key":"444_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijid.2020.06.067","volume":"98","author":"J Amzat","year":"2020","unstructured":"Amzat J, Aminu K, Kolo VI, Akinyele AA, Ogundairo JA, Danjibo CM. Coronavirus outbreak in Nigeria: burden and socio-medical response during the first 100 days. Int J Infect Dis. 2020;98:1\u201316.","journal-title":"Int J Infect Dis"},{"key":"444_CR8","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","volume":"15","author":"A Talevi","year":"2020","unstructured":"Talevi A, Bellera CL. Expert opinion on drug discovery challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov. 2020;15:397\u2013401.","journal-title":"Expert Opin Drug Discov"},{"key":"444_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13273","author":"J Jourdan","year":"2020","unstructured":"Jourdan J. Drug repositioning: a brief overview. J Pharm Pharmacol. 2020. https:\/\/doi.org\/10.1111\/jphp.13273.","journal-title":"J Pharm Pharmacol"},{"key":"444_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijantimicag.2018.03.012","volume":"52","author":"L Peyclit","year":"2019","unstructured":"Peyclit L, Baron SA, Yousfi H, Rolain J, Peyclit L, Baron SA, et al. Zidovudine: a salvage therapy for mcr-1 plasmid-mediated colistin-resistant bacterial infections? To cite this version: HAL Id: hal-01858892. Int J Antimicrob Agents. 2019;52:11\u20133.","journal-title":"Int J Antimicrob Agents"},{"key":"444_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.2174\/1568026616666160930131737","volume":"17","author":"V Soo","year":"2017","unstructured":"Soo V, Quezada H, Perez B, Martinez-vazquez M. Repurposing of anticancer drugs for the treatment of bacterial infections. Curr Top Med Chem. 2017;17:1157\u201376.","journal-title":"Curr Top Med Chem"},{"key":"444_CR12","first-page":"4539","volume":"24","author":"SA Meo","year":"2020","unstructured":"Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24:4539\u201347.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"444_CR13","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","volume":"56","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.","journal-title":"Int J Antimicrob Agents"},{"key":"444_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007016","author":"J Grein","year":"2020","unstructured":"Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMoa2007016.","journal-title":"N Engl J Med"},{"key":"444_CR15","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","volume":"11","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Chen V, Shannon CP, Wei X-S, Xiang X, Wang X, et al. Interferon-\u03b12b treatment for COVID-19. Front Immunol. 2020;11:1061. https:\/\/doi.org\/10.3389\/fimmu.2020.01061.","journal-title":"Front Immunol"},{"key":"444_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jinf.2020.05.046","volume":"81","author":"L Lansbury","year":"2020","unstructured":"Lansbury L, Lim B, Baskaran V, Lim WS. Co-infections in people with COVID-19: a systematic review and meta-analysis. J Infect. 2020;81:266\u201375.","journal-title":"J Infect"},{"key":"444_CR17","doi-asserted-by":"publisher","first-page":"198005","DOI":"10.1016\/j.virusres.2020.198005","volume":"285","author":"X Zhu","year":"2020","unstructured":"Zhu X, Ge Y, Wu T, Zhao K, Chen Y, Wu B, et al. Co-infection with respiratory pathogens among COVID-2019 cases. Virus Res. 2020;285:198005.","journal-title":"Virus Res"},{"key":"444_CR18","doi-asserted-by":"publisher","first-page":"e20200961","DOI":"10.1542\/peds.2020-0961","volume":"146","author":"Q Wu","year":"2020","unstructured":"Wu Q, Xing Y, Shi L, Li W, Gao Y, Pan S, et al. Coinfection and other clinical characteristics of COVID-19 in children. Pediatrics. 2020;146:e20200961.","journal-title":"Pediatrics"},{"key":"444_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/106002809202600112","volume":"26","author":"N Bahal","year":"1992","unstructured":"Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother. 1992;26:46\u201355.","journal-title":"Ann Pharmacother"},{"key":"444_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","volume":"1","author":"PB Madrid","year":"2015","unstructured":"Madrid PB, Panchal RG, Warren TK, Shurtleff AC, Endsley AN, Green CE, et al. Evaluation of ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015;1:317\u201326.","journal-title":"ACS Infect Dis"},{"key":"444_CR21","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00394-19","author":"C Li","year":"2019","unstructured":"Li C, Zu S, Deng Y-Q, Li D, Parvatiyar K, Quanquin N, et al. Azithromycin protects against Zika virus Infection by upregulating virus-induced type I and III interferon responses. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.00394-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"444_CR22","doi-asserted-by":"publisher","first-page":"e01152","DOI":"10.1128\/AAC.01152-17","volume":"61","author":"M Iannetta","year":"2017","unstructured":"Iannetta M, Ippolito G, Nicastri E. Azithromycin shows anti-Zika virus activity in human glial cells. Antimicrob Agents Chemother. 2017;61(9):e01152. https:\/\/doi.org\/10.1128\/AAC.01152-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"444_CR23","doi-asserted-by":"publisher","first-page":"104591","DOI":"10.1016\/j.antiviral.2019.104591","volume":"171","author":"M Arikata","year":"2019","unstructured":"Arikata M, Itoh Y, Shichinohe S, Nakayama M, Ishigaki H, Kinoshita T, et al. Efficacy of clarithromycin against H5N1 and H7N9 avian influenza a virus infection in cynomolgus monkeys. Antiviral Res. 2019;171:104591.","journal-title":"Antiviral Res"},{"key":"444_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cimid.2017.11.002","volume":"56","author":"E Takahashi","year":"2018","unstructured":"Takahashi E, Indalao IL, Sawabuchi T, Mizuno K, Sakai S, Kimoto T, et al. Clarithromycin suppresses induction of monocyte chemoattractant protein-1 and matrix metalloproteinase-9 and improves pathological changes in the lungs and heart of mice infected with influenza A virus. Comp Immunol Microbiol Infect Dis. 2018;56:6\u201313.","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"444_CR25","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1128\/AAC.31.12.1948","volume":"31","author":"AE Girard","year":"1987","unstructured":"Girard AE, Girard D, English AR, Gootz TD, Cimochowski CR, Faiella JA, et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob Agents Chemother. 1987;31:1948\u201354.","journal-title":"Antimicrob Agents Chemother"},{"key":"444_CR26","doi-asserted-by":"publisher","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","volume":"34","author":"P Gautret","year":"2020","unstructured":"Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Sevestre J, et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study. Travel Med Infect Dis. 2020;34:101663.","journal-title":"Travel Med Infect Dis"},{"key":"444_CR27","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/bcp.14335","volume":"86","author":"H Javelot","year":"2020","unstructured":"Javelot H, El-Hage W, Meyer G, Becker G, Michel B, Hingray C. COVID-19 and (hydroxy)chloroquine-azithromycin combination: should we take the risk for our patients? Br J Clin Pharmacol. 2020;86:1176\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"444_CR28","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101094","author":"K Gbinigie","year":"2020","unstructured":"Gbinigie K, Frie K. Should azithromycin be used to treat COVID-19? A rapid review. BJGP Open. 2020. https:\/\/doi.org\/10.3399\/bjgpopen20X101094.","journal-title":"BJGP Open"},{"key":"444_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.5582\/bst.2020.03058","volume":"14","author":"M Ohe","year":"2020","unstructured":"Ohe M, Shida H, Jodo S, Kusunoki Y, Seki M, Furuya K, et al. Macrolide treatment for COVID-19: will this be the way forward? Biosci Trends. 2020;14:159\u201360.","journal-title":"Biosci Trends"},{"key":"444_CR30","doi-asserted-by":"publisher","first-page":"101738","DOI":"10.1016\/j.tmaid.2020.101738","volume":"35","author":"M Million","year":"2020","unstructured":"Million M, Lagier J-C, Gautret P, Colson P, Fournier P-E, Amrane S, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: a retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020;35:101738.","journal-title":"Travel Med Infect Dis"},{"key":"444_CR31","doi-asserted-by":"publisher","first-page":"e13785","DOI":"10.1111\/dth.13785","volume":"33","author":"RA Schwartz","year":"2020","unstructured":"Schwartz RA, Suskind RM. Azithromycin and COVID-19 prompt early use at first signs of this infection in adults and children an approach worthy of consideration. Dermatol Ther. 2020;33:e13785.","journal-title":"Dermatol Ther"},{"key":"444_CR32","doi-asserted-by":"publisher","first-page":"104228","DOI":"10.1016\/j.micpath.2020.104228","volume":"145","author":"J Andreani","year":"2020","unstructured":"Andreani J, Le Bideau M, Duflot I, Jardot P, Rolland C, Boxberger M, et al. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect. Microb Pathog. 2020;145:104228.","journal-title":"Microb Pathog"},{"key":"444_CR33","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1006\/excr.2002.5613","volume":"281","author":"D Tyteca","year":"2002","unstructured":"Tyteca D, Van Der Smissen P, Mettlen M, Van Bambeke F, Tulkens PM, Mingeot-Leclercq M-P, et al. Azithromycin, a lysosomotropic antibiotic, has distinct effects on fluid-phase and receptor-mediated endocytosis, but does not impair phagocytosis in J774 macrophages. Exp Cell Res. 2002;281:86\u2013100.","journal-title":"Exp Cell Res"},{"issue":"2","key":"444_CR34","doi-asserted-by":"publisher","first-page":"106053","DOI":"10.1016\/j.ijantimicag.2020.106053","volume":"56","author":"A Pani","year":"2020","unstructured":"Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents. 2020;56(2):106053","journal-title":"Int J Antimicrob Agents"},{"key":"444_CR35","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.intimp.2016.09.012","volume":"40","author":"S-J Lin","year":"2016","unstructured":"Lin S-J, Kuo M-L, Hsiao H-S, Lee P-T. Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4+ T cells. Int Immunopharmacol. 2016;40:318\u201326.","journal-title":"Int Immunopharmacol"},{"key":"444_CR36","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0149-2918(96)80179-2","volume":"18","author":"GW Amsden","year":"1996","unstructured":"Amsden GW. Erythromycin, clarithromycin, and azithromycin: are the differences real? Clin Ther. 1996;18:56\u201372.","journal-title":"Clin Ther"},{"key":"444_CR37","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12941-020-00358-y","volume":"19","author":"J Mill\u00e1n-O\u00f1ate","year":"2020","unstructured":"Mill\u00e1n-O\u00f1ate J, Millan W, Mendoza LA, S\u00e1nchez CG, Fernandez-Suarez H, Bonilla-Aldana DK, et al. Successful recovery of COVID-19 pneumonia in a patient from Colombia after receiving chloroquine and clarithromycin. Ann Clin Microbiol Antimicrob. 2020;19:16.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"444_CR38","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/cr030103a","volume":"105","author":"D Kahne","year":"2005","unstructured":"Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev Am Chem Soc. 2005;105:425\u201348.","journal-title":"Chem Rev Am Chem Soc"},{"key":"444_CR39","doi-asserted-by":"publisher","first-page":"9218","DOI":"10.1074\/jbc.M116.716100","volume":"291","author":"N Zhou","year":"2016","unstructured":"Zhou N, Pan T, Zhang J, Li Q, Zhang X, Bai C, et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome\/lysosome and block the entry of ebola virus, middle east respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem. 2016;291:9218\u201332.","journal-title":"J Biol Chem"},{"key":"444_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2015.11.003","volume":"125","author":"Y Wang","year":"2016","unstructured":"Wang Y, Cui R, Li G, Gao Q, Yuan S, Altmeyer R, et al. Teicoplanin inhibits ebola pseudovirus infection in cell culture. Antiviral Res. 2016;125:1\u20137.","journal-title":"Antiviral Res"},{"key":"444_CR41","doi-asserted-by":"publisher","first-page":"105944","DOI":"10.1016\/j.ijantimicag.2020.105944","volume":"55","author":"SA Baron","year":"2020","unstructured":"Baron SA, Devaux C, Colson P, Raoult D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of COVID-19? Int J Antimicrob Agents. 2020;55:105944.","journal-title":"Int J Antimicrob Agents"},{"key":"444_CR42","doi-asserted-by":"publisher","first-page":"106029","DOI":"10.1016\/j.ijantimicag.2020.106029","volume":"56","author":"G Ceccarelli","year":"2020","unstructured":"Ceccarelli G, Alessandri F, d\u2019Ettorre G, Borrazzo C, Spagnolello O, Oliva A, et al. Is teicoplanin a complementary treatment option for COVID-19? The question remains. Int J Antimicrob Agents. 2020;56:106029.","journal-title":"Int J Antimicrob Agents"},{"key":"444_CR43","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.05.935387","author":"J Zhang","year":"2020","unstructured":"Zhang J, Ma X, Yu F, Liu J, Zou F, Pan T, et al. Teicoplanin potently blocks the cell entry of 2019-nCoV. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.02.05.935387.","journal-title":"bioRxiv"},{"key":"444_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1128\/MMBR.65.2.232-260.2001","volume":"65","author":"I Chopra","year":"2001","unstructured":"Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev Am Soc Microbiol. 2001;65:232\u201360.","journal-title":"Microbiol Mol Biol Rev Am Soc Microbiol"},{"key":"444_CR45","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00705-013-1880-7","volume":"159","author":"HA Rothan","year":"2014","unstructured":"Rothan HA, Mohamed Z, Paydar M, Rahman NA, Yusof R. Inhibitory effect of doxycycline against dengue virus replication in vitro. Arch Virol. 2014;159:711\u20138.","journal-title":"Arch Virol"},{"key":"444_CR46","first-page":"681","volume":"30","author":"HA Rothan","year":"2013","unstructured":"Rothan HA, Buckle MJ, Ammar YA, Mohammadjavad P, Shatrah O, Noorsaadah AR, et al. Study the antiviral activity of some derivatives of tetracycline and non-steroid anti inflammatory drugs towards dengue virus. Trop Biomed. 2013;30:681\u201390.","journal-title":"Trop Biomed"},{"key":"444_CR47","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1358\/mf.1998.20.8.487489","volume":"20","author":"FG Sturtz","year":"1998","unstructured":"Sturtz FG. Antimurine retroviral effect of doxycycline. Methods Find Exp Clin Pharmacol. 1998;20:643.","journal-title":"Methods Find Exp Clin Pharmacol"},{"key":"444_CR48","first-page":"61","volume":"41","author":"S Skulason","year":"2012","unstructured":"Skulason S, Holbrook WP, Thormar H, Gunnarsson GB, Kristmundsdottir T. A study of the clinical activity of a gel combining monocaprin and doxycycline: a novel treatment for herpes labialis. J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2012;41:61\u20137.","journal-title":"J Oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol"},{"issue":"22","key":"444_CR49","doi-asserted-by":"publisher","first-page":"fnv195","DOI":"10.1093\/femsle\/fnv195","volume":"362","author":"Z Wu","year":"2015","unstructured":"Wu Z, Wang X, Wei J, Li B, Shao D, Li Y, et al. Antiviral activity of doxycycline against vesicular stomatitis virus in vitro. FEMS Microbiol Lett. 2015;362(22):fnv195.","journal-title":"FEMS Microbiol Lett."},{"key":"444_CR50","first-page":"11555","volume":"77","author":"MJ Bick","year":"2003","unstructured":"Bick MJ, Carroll J-WN, Gao G, Goff SP, Rice CM, MacDonald MR. Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol Am Soc Microbiol J. 2003;77:11555\u201362.","journal-title":"J Virol Am Soc Microbiol J"},{"issue":"2","key":"444_CR51","doi-asserted-by":"publisher","first-page":"e01909","DOI":"10.1128\/JVI.01909-16","volume":"91","author":"Q Tang","year":"2017","unstructured":"Tang Q, Wang X, Gao G. The short form of the zinc finger antiviral protein inhibits influenza a virus protein expression and is antagonized by the virus-encoded NS1. J Virol. 2017;91(2):e01909\u201316.","journal-title":"J Virol"},{"key":"444_CR52","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.18632\/aging.103001","volume":"12","author":"C Sargiacomo","year":"2020","unstructured":"Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging. 2020;12:6511\u20137.","journal-title":"Aging"},{"key":"444_CR53","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1574891X10666150410153839","volume":"10","author":"TM Fredeking","year":"2015","unstructured":"Fredeking TM, Zavala-Castro JE, Gonz\u00e1lez-Mart\u00ednez P, Moguel-Rodr\u00edguez W, Sanchez EC, Foster MJ, et al. Dengue patients treated with doxycycline showed lower mortality associated to a reduction in IL-6 and TNF levels. Recent Patents Anti-Infect Drug Disc. 2015;10:51\u20138.","journal-title":"Recent Patents Anti-Infect Drug Disc"},{"key":"444_CR54","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet Lond Engl. 2020;395:1033\u20134.","journal-title":"Lancet Lond Engl"},{"key":"444_CR55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jbspin.2020.03.011","volume":"87","author":"L Quartuccio","year":"2020","unstructured":"Quartuccio L, Semerano L, Benucci M, Boissier M-C, De Vita S. Urgent avenues in the treatment of COVID-19: targeting downstream inflammation to prevent catastrophic syndrome. Joint Bone Spine. 2020;87:191\u20133.","journal-title":"Joint Bone Spine"},{"key":"444_CR56","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"C Wu","year":"2020","unstructured":"Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10:766\u201388.","journal-title":"Acta Pharm Sin B"},{"key":"444_CR57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1586\/14787210.4.2.291","volume":"4","author":"ED Clercq","year":"2006","unstructured":"Clercq ED. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther (Taylor and Francis). 2006;4:291\u2013302.","journal-title":"Expert Rev Anti Infect Ther (Taylor and Francis)"},{"key":"444_CR58","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1021\/acs.jcim.0c00179","volume":"60","author":"J Wang","year":"2020","unstructured":"Wang J. Fast identification of possible drug treatment of coronavirus disease-19 (COVID-19) through computational drug repurposing study. J Chem Inf Model. 2020;60:3277\u201386.","journal-title":"J Chem Inf Model"},{"key":"444_CR59","doi-asserted-by":"publisher","first-page":"e1800141","DOI":"10.1002\/ardp.201800141","volume":"351","author":"HAA Ezelarab","year":"2018","unstructured":"Ezelarab HAA, Abbas SH, Hassan HA, Abuo-Rahma GE-DA. Recent updates of fluoroquinolones as antibacterial agents. Arch Pharm (Weinheim). 2018;351:e1800141.","journal-title":"Arch Pharm (Weinheim)"},{"key":"444_CR60","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10096-014-2296-3","volume":"34","author":"A Dalhoff","year":"2015","unstructured":"Dalhoff A. Antiviral, antifungal, and antiparasitic activities of fluoroquinolones optimized for treatment of bacterial infections: a puzzling paradox or a logical consequence of their mode of action? Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 2015;34:661\u20138.","journal-title":"Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol"},{"key":"444_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0166-3542(87)90064-7","volume":"8","author":"S Ikeda","year":"1987","unstructured":"Ikeda S, Yazawa M, Nishimura C. Antiviral activity and inhibition of topoisomerase by ofloxacin, a new quinolone derivative. Antiviral Res. 1987;8:103\u201313.","journal-title":"Antiviral Res"},{"key":"444_CR62","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2174\/1568005043340920","volume":"4","author":"S Richter","year":"2004","unstructured":"Richter S, Parolin C, Palumbo M, Pal\u00f9 G. Antiviral properties of quinolone-based drugs. Curr Drug Targets Infect Disord. 2004;4:111\u20136.","journal-title":"Curr Drug Targets Infect Disord"},{"key":"444_CR63","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1177\/095632029800900504","volume":"9","author":"M Witvrouw","year":"1998","unstructured":"Witvrouw M, Daelemans D, Pannecouque C, Neyts J, Andrei G, Snoeck R, et al. Broad-spectrum antiviral activity and mechanism of antiviral action of the fluoroquinolone derivative K-12. Antivir Chem Chemother. 1998;9:403\u201311.","journal-title":"Antivir Chem Chemother"},{"issue":"7","key":"444_CR64","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.arcmed.2020.06.004","volume":"51","author":"I Karampela","year":"2020","unstructured":"Karampela I, Dalamaga M. Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch Med Res. 2020;51(7):741\u20132.","journal-title":"Arch Med Res"},{"issue":"6","key":"444_CR65","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s43440-020-00169-0","volume":"72","author":"K Marciniec","year":"2020","unstructured":"Marciniec K, Beberok A, Boryczka S, Wrze\u015bniok D. Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis. Pharmacol Rep. 2020;72(6):1553\u201361.","journal-title":"Pharmacol Rep"},{"key":"444_CR66","doi-asserted-by":"publisher","DOI":"10.7326\/M20-2189","author":"JP Metlay","year":"2020","unstructured":"Metlay JP, Waterer GW. Treatment of community-acquired pneumonia during the coronavirus disease (COVID-19) pandemic. Ann Intern Med. 2020. https:\/\/doi.org\/10.7326\/M20-2189.","journal-title":"Ann Intern Med"},{"key":"444_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/S1473-3099(03)00658-3","volume":"3","author":"A Dalhoff","year":"2003","unstructured":"Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003;3:359\u201371.","journal-title":"Lancet Infect Dis"},{"key":"444_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1179\/joc.2002.14.1.3","volume":"14","author":"K Riesbeck","year":"2002","unstructured":"Riesbeck K. Immunomodulating activity of quinolones: review. J Chemother Florence Italy. 2002;14:3\u201312.","journal-title":"J Chemother Florence Italy"},{"key":"444_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-46718-4_14","volume-title":"Antimicrobial drug resistance","author":"AW Serio","year":"2017","unstructured":"Serio AW, Magalhaes ML, Blanchard JS, Connolly LE. Aminoglycosides: mechanisms of action and resistance. In: Mayers D, Sobel J, Ouellette M, Kaye K, Marchaim D, editors. Antimicrobial drug resistance. Cham: Springer; 2017. https:\/\/doi.org\/10.1007\/978-3-319-46718-4_14."},{"issue":"6","key":"444_CR70","doi-asserted-by":"publisher","first-page":"a027029","DOI":"10.1101\/cshperspect.a027029","volume":"6","author":"KM Krause","year":"2016","unstructured":"Krause KM, Serio AW, Kane TR, Connolly LE. Aminoglycosides: an overview. Cold Spring Harb Perspect Med. 2016;6(6):a027029.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1","key":"444_CR71","doi-asserted-by":"publisher","first-page":"e00632-18","DOI":"10.1128\/mSphere.00632-18","volume":"4","author":"MA Woods Acevedo","year":"2019","unstructured":"Woods Acevedo MA, Erickson AK, Pfeiffer JK. The antibiotic neomycin enhances coxsackievirus plaque formation. mSphere. 2019;4(1):e00632-18.","journal-title":"mSphere"},{"key":"444_CR72","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41564-018-0138-2","volume":"3","author":"S Gopinath","year":"2018","unstructured":"Gopinath S, Kim MV, Rakib T, Wong PW, van Zandt M, Barry NA, et al. Topical application of aminoglycoside antibiotics enhances host resistance to viral infections in a microbiota-independent manner. Nat Microbiol. 2018;3:611\u201321.","journal-title":"Nat Microbiol"},{"key":"444_CR73","doi-asserted-by":"publisher","first-page":"109984","DOI":"10.1016\/j.mehy.2020.109984","volume":"144","author":"NSS Chalichem","year":"2020","unstructured":"Chalichem NSS, Bethapudi B, Mundkinajeddu D. Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: plausible mechanism for repurposing strategy. Med Hypotheses. 2020;144:109984.","journal-title":"Med Hypotheses"},{"key":"444_CR74","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.2174\/1381612824666180403114615","volume":"24","author":"Z Khurshid","year":"2018","unstructured":"Khurshid Z, Zafar MS, Naseem M, Khan RS, Najeeb S. Human oral defensins antimicrobial peptides: a future promising antimicrobial drug. Curr Pharm Des. 2018;24:1130\u20137.","journal-title":"Curr Pharm Des"},{"key":"444_CR75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1146\/annurev-virology-101416-041734","volume":"4","author":"MK Holly","year":"2017","unstructured":"Holly MK, Diaz K, Smith JG. Defensins in viral infection and pathogenesis. Annu Rev Virol. 2017;4:369\u201391.","journal-title":"Annu Rev Virol"},{"key":"444_CR76","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4062\/biomolther.2017.172","volume":"26","author":"MS Park","year":"2018","unstructured":"Park MS, Kim JI, Lee I, Park S, Bae J-Y, Park M-S. Towards the application of human defensins as antivirals. Biomol Ther. 2018;26:242\u201354.","journal-title":"Biomol Ther"},{"key":"444_CR77","doi-asserted-by":"publisher","first-page":"e95","DOI":"10.1371\/journal.pbio.1000095","volume":"7","author":"N Venkataraman","year":"2009","unstructured":"Venkataraman N, Cole AL, Ruchala P, Waring AJ, Lehrer RI, Stuchlik O, et al. Reawakening retrocyclins: ancestral human defensins active against HIV-1. PLoS Biol. 2009;7:e95.","journal-title":"PLoS Biol"},{"key":"444_CR78","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1016\/j.jmb.2013.09.038","volume":"425","author":"SS Wilson","year":"2013","unstructured":"Wilson SS, Wiens ME, Smith JG. Antiviral mechanisms of human defensins. J Mol Biol. 2013;425:4965\u201380.","journal-title":"J Mol Biol"},{"issue":"5","key":"444_CR79","doi-asserted-by":"publisher","first-page":"317","DOI":"10.18176\/jiaci.0567","volume":"30","author":"A Izquierdo-Dominguez","year":"2020","unstructured":"Izquierdo-Dominguez A, Rojas-Lechuga MJ, Mullol J, Alobid I. Olfactory dysfunction in the COVID-19 outbreak. J Investig Allergol Clin Immunol. 2020;30(5):317\u201326.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"444_CR80","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2165\/11591980-000000000-00000","volume":"28","author":"U Thiem","year":"2011","unstructured":"Thiem U, Heppner H-J, Pientka L. Elderly patients with community-acquired pneumonia: optimal treatment strategies. Drugs Aging. 2011;28:519\u201337.","journal-title":"Drugs Aging"},{"key":"444_CR81","doi-asserted-by":"publisher","DOI":"10.1080\/07391102.2020.1777904","author":"AB Durojaiye","year":"2020","unstructured":"Durojaiye AB, Clarke J-RD, Stamatiades GA, Wang C. Repurposing cefuroxime for treatment of COVID-19: a scoping review of in silico studies. J Biomol Struct Dyn. 2020. https:\/\/doi.org\/10.1080\/07391102.2020.1777904.","journal-title":"J Biomol Struct Dyn"},{"key":"444_CR82","doi-asserted-by":"publisher","first-page":"106053","DOI":"10.1016\/j.ijantimicag.2020.106053","volume":"56","author":"A Pani","year":"2020","unstructured":"Pani A, Lauriola M, Romandini A, Scaglione F. Macrolides and viral infections: focus on azithromycin in COVID-19 pathology. Int J Antimicrob Agents. 2020;56:106053.","journal-title":"Int J Antimicrob Agents"},{"key":"444_CR83","doi-asserted-by":"publisher","first-page":"100684","DOI":"10.1016\/j.nmni.2020.100684","volume":"35","author":"R Choudhary","year":"2020","unstructured":"Choudhary R, Sharma AK, Choudhary R. Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance. N Microbes N Infect. 2020;35:100684.","journal-title":"N Microbes N Infect."},{"key":"444_CR84","first-page":"92","volume":"48","author":"F Touret","year":"2020","unstructured":"Touret F, Gilles M, Barral K, Nougair\u00e8de A, Decroly E, de Lamballerie X, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. bioRxiv (Cold Spring Harbor Laboratory). 2020;48:92.","journal-title":"bioRxiv (Cold Spring Harbor Laboratory)"},{"key":"444_CR85","doi-asserted-by":"publisher","first-page":"110011","DOI":"10.1016\/j.mehy.2020.110011","volume":"144","author":"N Sathyamoorthy","year":"2020","unstructured":"Sathyamoorthy N, Chintamaneni PK, Chinni S. Plausible role of combination of chlorpromazine hydrochloride and teicoplanin against COVID-19. Med Hypotheses. 2020;144:110011.","journal-title":"Med Hypotheses"},{"key":"444_CR86","first-page":"609","volume":"9","author":"B He","year":"2020","unstructured":"He B, Garmire L. Prediction of repurposed drugs for treating lung injury in COVID-19. ArXiv. 2020;9:609.","journal-title":"ArXiv."},{"key":"444_CR87","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1002\/phar.2395","volume":"40","author":"M Sodhi","year":"2020","unstructured":"Sodhi M, Etminan M. Therapeutic potential for tetracyclines in the treatment of COVID-19. Pharmacotherapy (Hoboken: Wiley). 2020;40:487\u20138.","journal-title":"Pharmacotherapy (Hoboken: Wiley)"},{"key":"444_CR88","doi-asserted-by":"publisher","first-page":"e13437","DOI":"10.1111\/dth.13437","volume":"33","author":"C Conforti","year":"2020","unstructured":"Conforti C, Giuffrida R, Zalaudek I, Di Meo N. Doxycycline, a widely used antibiotic in dermatology with a possible anti-inflammatory action against IL-6 in COVID-19 outbreak. Dermatol Ther. 2020;33:e13437.","journal-title":"Dermatol Ther"},{"key":"444_CR89","doi-asserted-by":"publisher","first-page":"109768","DOI":"10.1016\/j.mehy.2020.109768","volume":"140","author":"A Farouk","year":"2020","unstructured":"Farouk A, Salman S. Dapsone and doxycycline could be potential treatment modalities for COVID-19. Med Hypotheses. 2020;140:109768.","journal-title":"Med Hypotheses"},{"key":"444_CR90","doi-asserted-by":"publisher","first-page":"e00864","DOI":"10.1016\/j.idcr.2020.e00864","volume":"21","author":"AE Malek","year":"2020","unstructured":"Malek AE, Granwehr BP, Kontoyiannis DP. Doxycycline as a potential partner of COVID-19 therapies. IDCases. 2020;21:e00864.","journal-title":"IDCases."},{"key":"444_CR91","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13810","author":"G Szolnoky","year":"2020","unstructured":"Szolnoky G. Further aspects of doxycycline therapy in COVID-19. Dermatol Ther. 2020;. https:\/\/doi.org\/10.1111\/dth.13810.","journal-title":"Dermatol Ther"},{"key":"444_CR92","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3389\/fmed.2020.00200","volume":"7","author":"C Bonzano","year":"2020","unstructured":"Bonzano C, Borroni D, Lancia A, Bonzano E. Doxycycline: from ocular rosacea to COVID-19 anosmia. New insight into the coronavirus outbreak. Front Med. 2020;7:200.","journal-title":"Front Med"}],"container-title":["Annals of Clinical Microbiology and Antimicrobials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-021-00444-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12941-021-00444-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12941-021-00444-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T06:10:13Z","timestamp":1675318213000},"score":1,"resource":{"primary":{"URL":"https:\/\/ann-clinmicrob.biomedcentral.com\/articles\/10.1186\/s12941-021-00444-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,21]]},"references-count":92,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["444"],"URL":"https:\/\/doi.org\/10.1186\/s12941-021-00444-9","relation":{},"ISSN":["1476-0711"],"issn-type":[{"value":"1476-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,21]]},"assertion":[{"value":"19 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No competing interests were disclosed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37"}}